AR121842A1 - Compuesto de benzimidazol para el tratamiento de trastornos metabólicos - Google Patents
Compuesto de benzimidazol para el tratamiento de trastornos metabólicosInfo
- Publication number
- AR121842A1 AR121842A1 ARP210100985A ARP210100985A AR121842A1 AR 121842 A1 AR121842 A1 AR 121842A1 AR P210100985 A ARP210100985 A AR P210100985A AR P210100985 A ARP210100985 A AR P210100985A AR 121842 A1 AR121842 A1 AR 121842A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzimidazole compound
- treatment
- metabolic disorders
- metabolites
- solvates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención, de manera general, concierne a un compuesto de benzimidazol de fórmula (1) para el tratamiento de la obesidad, la diabetes, la enfermedad del hígado graso no alcohólica y la esteatohepatitis no alcohólica: o sales, cristales, hidratos, profármacos, metabolitos o solvatos farmacéuticamente aceptables del mismo. Reivindicación 1: Un compuesto de bencimidazol de la fórmula (1) o sales, cristales, hidratos, solvatos, prodrogas o metabolitos del mismo farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063010128P | 2020-04-15 | 2020-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121842A1 true AR121842A1 (es) | 2022-07-13 |
Family
ID=78083461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100985A AR121842A1 (es) | 2020-04-15 | 2021-04-14 | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230128304A1 (es) |
EP (1) | EP4136079A4 (es) |
JP (1) | JP2023522062A (es) |
KR (1) | KR20230002427A (es) |
CN (1) | CN115335363A (es) |
AR (1) | AR121842A1 (es) |
AU (1) | AU2021256476A1 (es) |
CA (1) | CA3171746A1 (es) |
CL (1) | CL2022002821A1 (es) |
CO (1) | CO2022012616A2 (es) |
EC (1) | ECSP22078679A (es) |
GB (1) | GB2609793B (es) |
MX (1) | MX2022009872A (es) |
PE (1) | PE20221568A1 (es) |
WO (1) | WO2021207816A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124463A (en) * | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
AU2003902860A0 (en) * | 2003-06-06 | 2003-06-26 | Daicel Chemical Industries, Ltd | Benzimidazole compounds |
ES2331274B1 (es) * | 2007-10-25 | 2010-10-21 | Ferrer Internacional, S.A. | Compuesto de indolina. |
AU2009296820B2 (en) * | 2008-09-26 | 2014-03-20 | Merck Sharp & Dohme Llc | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
ES2711808B2 (es) * | 2017-11-02 | 2020-03-13 | Univ Granada | Uso de un agonista de melatonina para inducir la para inducir adipocitos beige en el tejido adiposo blanco |
-
2021
- 2021-04-14 AR ARP210100985A patent/AR121842A1/es unknown
- 2021-04-15 KR KR1020227035995A patent/KR20230002427A/ko unknown
- 2021-04-15 CA CA3171746A patent/CA3171746A1/en active Pending
- 2021-04-15 WO PCT/BR2021/050158 patent/WO2021207816A1/en active Search and Examination
- 2021-04-15 US US17/915,248 patent/US20230128304A1/en active Pending
- 2021-04-15 MX MX2022009872A patent/MX2022009872A/es unknown
- 2021-04-15 CN CN202180028308.5A patent/CN115335363A/zh active Pending
- 2021-04-15 AU AU2021256476A patent/AU2021256476A1/en active Pending
- 2021-04-15 PE PE2022001524A patent/PE20221568A1/es unknown
- 2021-04-15 GB GB2215434.8A patent/GB2609793B/en active Active
- 2021-04-15 JP JP2022562996A patent/JP2023522062A/ja active Pending
- 2021-04-15 EP EP21788866.8A patent/EP4136079A4/en active Pending
-
2022
- 2022-09-05 CO CONC2022/0012616A patent/CO2022012616A2/es unknown
- 2022-10-11 EC ECSENADI202278679A patent/ECSP22078679A/es unknown
- 2022-10-13 CL CL2022002821A patent/CL2022002821A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2022012616A2 (es) | 2022-10-21 |
CA3171746A1 (en) | 2021-10-21 |
EP4136079A1 (en) | 2023-02-22 |
AU2021256476A1 (en) | 2022-08-25 |
MX2022009872A (es) | 2022-08-22 |
GB2609793B (en) | 2024-05-08 |
PE20221568A1 (es) | 2022-10-06 |
GB2609793A (en) | 2023-02-15 |
GB2609793A8 (en) | 2023-03-22 |
KR20230002427A (ko) | 2023-01-05 |
JP2023522062A (ja) | 2023-05-26 |
CL2022002821A1 (es) | 2023-04-10 |
ECSP22078679A (es) | 2022-11-30 |
EP4136079A4 (en) | 2024-05-15 |
US20230128304A1 (en) | 2023-04-27 |
CN115335363A (zh) | 2022-11-11 |
GB202215434D0 (en) | 2022-11-30 |
WO2021207816A1 (en) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
DOP2020000037A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
ES2529890T3 (es) | Agentes para el tratamiento de trastornos que implican la modulación de los receptores rianodina | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
CU20190080A7 (es) | Derivados de isoindolina útiles para tratar la esteatohepatitis no alcohólica y otras enfermedades de curación disfuncional del tejido y fibrosis | |
DOP2023000196A (es) | Compuestos moduladores de fxr (nr1h4) | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
AR069165A1 (es) | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia | |
AR062402A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento del cancer de piel | |
CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
MA41389A1 (fr) | Utilisation de sulfones tricycliques en tant que modulateurs de rory | |
NZ721645A (en) | Compounds for use as gpr120 agonists | |
AR062401A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis | |
CO2021000932A2 (es) | Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma | |
AR087803A1 (es) | N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla | |
ZA202206481B (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
MX2021015325A (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa. | |
PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
BR112022018515A2 (pt) | Terapia de combinação para leucemia mieloide aguda | |
CL2022001357A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
MX2023003825A (es) | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. | |
AR121842A1 (es) | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos | |
MX2020004667A (es) | Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas. | |
PA8787001A1 (es) | " derivados de macrolactona" |